Literature DB >> 26396689

Novel 2-Carbonylbenzo[b]thiophene 1,1-Dioxide Derivatives as Potent Inhibitors of STAT3 Signaling Pathway.

Peng Ji1, Xin Xu2, Shuhua Ma3, Junchao Fan1, Qiang Zhou1, Xinliang Mao2, Chunhua Qiao4.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for cancer therapy. In this study, a series of 2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives (CBT) were designed to inhibit the STAT3 SH2 domain phosphorylation site Try 705. We demonstrated that incorporation of basic flexible groups through amide bond linkage to benzo[b]thiophene 1,1-dioxide (BTP) achieved compounds with higher antiproliferative potency than BTP itself. The most potent compound 6o, as indicated from luciferase reporter gene assay, inhibited the STAT3 pathway by decreasing the phosphorylation level of STAT3 Tyr705, while the phosphorylation level of other upstream tyrosine kinases in this pathway was not significantly inhibited. Compound 6o was also shown to trigger ROS generation and accumulation, thus consequently attributed partially to the observed cell apoptosis. This study provided important structural information for the development of inhibitors targeting the STAT3 pathway.

Entities:  

Keywords:  2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives; STAT3; antiproliferative activity; apoptosis; inhibitor; reactive oxygen species

Year:  2015        PMID: 26396689      PMCID: PMC4569881          DOI: 10.1021/acsmedchemlett.5b00228

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  32 in total

Review 1.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

2.  Validating Stat3 in cancer therapy.

Authors:  James E Darnell
Journal:  Nat Med       Date:  2005-06       Impact factor: 53.440

Review 3.  STAT3 signaling: anticancer strategies and challenges.

Authors:  Paul A Johnston; Jennifer R Grandis
Journal:  Mol Interv       Date:  2011-02

4.  Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.

Authors:  Lin-Hung Wei; Min-Liang Kuo; Chi-An Chen; Chia-Hung Chou; Kuo-Bau Lai; Chien-Nan Lee; Chang-Yao Hsieh
Journal:  Oncogene       Date:  2003-03-13       Impact factor: 9.867

5.  Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).

Authors:  Haijun Chen; Zhengduo Yang; Chunyong Ding; Ailian Xiong; Christopher Wild; Lili Wang; Na Ye; Guoshuai Cai; Rudolfo M Flores; Ye Ding; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2014-05-22       Impact factor: 6.514

6.  Anticancer activity and SAR studies of substituted 1,4-naphthoquinones.

Authors:  Deepak Bhasin; Somsundaram N Chettiar; Jonathan P Etter; May Mok; Pui-Kai Li
Journal:  Bioorg Med Chem       Date:  2013-05-18       Impact factor: 3.641

7.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Authors:  Hui Song; Renxiao Wang; Shaomeng Wang; Jiayuh Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

8.  Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.

Authors:  Haijun Chen; Zhengduo Yang; Chunyong Ding; Lili Chu; Yusong Zhang; Kristin Terry; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  ACS Med Chem Lett       Date:  2013-01-15       Impact factor: 4.345

9.  New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells.

Authors:  M M Alonso; A Asumendi; J Villar; M J Gil; V Martínez-Merino; I J Encío; M Migliaccio
Journal:  Oncogene       Date:  2003-06-12       Impact factor: 9.867

10.  The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.

Authors:  Sarah Ball; Chenglong Li; Pui-Kai Li; Jiayuh Lin
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

View more
  4 in total

Review 1.  Targeting Transcription Factors for Cancer Treatment.

Authors:  Mélanie Lambert; Samy Jambon; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

2.  The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against Breast Cancer.

Authors:  Chen Fan; Yijie Wang; Hui Huang; Wenzhen Li; Jialin Ma; Dongping Yao; Zijun Tang; Taixiong Xue; Liyang Ha; Yan Ren; Yiwen Zhang; Qin Wang; Yongmei Xie; Yi Luo; Rui Tan; Jian Gu
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 3.  Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations.

Authors:  Sheng Tang; Zhihui Zhou; Zhiyan Jiang; Wufu Zhu; Dan Qiao
Journal:  Molecules       Date:  2022-02-28       Impact factor: 4.411

Review 4.  Targeting STAT3 in Cancer Immunotherapy.

Authors:  Sailan Zou; Qiyu Tong; Bowen Liu; Wei Huang; Yan Tian; Xianghui Fu
Journal:  Mol Cancer       Date:  2020-09-24       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.